1. Home
  2. HHS vs MBRX Comparison

HHS vs MBRX Comparison

Compare HHS & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Harte-Hanks Inc.

HHS

Harte-Hanks Inc.

HOLD

Current Price

$2.39

Market Cap

17.1M

ML Signal

HOLD

Logo Moleculin Biotech Inc.

MBRX

Moleculin Biotech Inc.

HOLD

Current Price

$2.12

Market Cap

16.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HHS
MBRX
Founded
1923
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Advertising
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.1M
16.1M
IPO Year
1994
2016

Fundamental Metrics

Financial Performance
Metric
HHS
MBRX
Price
$2.39
$2.12
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$61.00
AVG Volume (30 Days)
3.0K
353.3K
Earning Date
05-14-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
97.35
N/A
EPS
N/A
N/A
Revenue
$159,570,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.07
$0.26
52 Week High
$4.32
$7.98

Technical Indicators

Market Signals
Indicator
HHS
MBRX
Relative Strength Index (RSI) 49.24 38.82
Support Level $2.28 $2.00
Resistance Level $2.94 $2.58
Average True Range (ATR) 0.10 0.13
MACD 0.02 -0.03
Stochastic Oscillator 41.67 13.48

Price Performance

Historical Comparison
HHS
MBRX

About HHS Harte-Hanks Inc.

Harte-Hanks Inc is a customer experience company. The company operates three business segments: Revenue Solutions; Customer Care; and Fulfillment & Logistics Services. It derives maximum revenue from Fulfillment & Logistics Services segment. The Fulfillment & Logistics Services segment includes printing, lettershop, advanced mail optimization (including commingling services), logistics and transportation optimization, monitoring and tracking, to support traditional and specialized mailings. The company has a geographic presence in the United States and Other countries. The majority of the revenue is earned from the United States.

About MBRX Moleculin Biotech Inc.

Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.

Share on Social Networks: